GenSight Biologics SA, a clinical-stage biopharma company specializing in gene therapies for retinal and central nervous system disorders, has recently completed a fundraising round, securing just under €1.7 million. This financial infusion was achieved through the issuance of ordinary shares, pre-funded warrants, and investor warrants. Following this transaction, the shares were admitted to trading on Euronext Paris, marking a significant step in the company’s capital-raising efforts.
The company, listed on the NYSE Euronext Paris, operates within the biotechnology sector of the health care industry. As of March 18, 2026, GenSight Biologics SA’s close price stood at €0.0838, with a market capitalization of €19,980,000. The company’s stock has experienced fluctuations over the past year, reaching a 52-week high of €0.3 on April 7, 2025, and a low of €0.0752 on February 2, 2026. The price-to-earnings ratio is currently at -0.648, reflecting the company’s status as a clinical-stage entity with no earnings.
GenSight Biologics SA’s primary focus is on the discovery, development, and commercialization of therapies targeting mitochondrial and neurodegenerative diseases affecting the eye and central nervous system. The company’s lead product candidate, GS010 (lenadogene nolparvovec), is currently in Phase III clinical trials for the treatment of Leber hereditary optic neuropathy (LHON). Despite the progress in clinical development, GS010 has not yet received marketing authorization in any jurisdiction.
The funds raised through the recent fundraising round are earmarked to support GenSight Biologics SA’s ongoing development activities and to extend its cash runway. This financial support is crucial for the company as it continues to advance its pipeline and seeks to bring its innovative therapies to market. In its announcement, GenSight Biologics SA also reminded investors of the inherent risks associated with its operations, as disclosed in its regulatory filings.
As GenSight Biologics SA progresses through the clinical development phases, the company remains focused on its mission to address unmet medical needs in the field of mitochondrial and neurodegenerative diseases. The successful completion of this fundraising round underscores the confidence of investors in the company’s potential to deliver transformative therapies to patients in need.
